Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the efficacy of Chanyanning granules in patients undergoing endoscopic resection of colorectal polyps with a basal diameter of 5-30 mm. From one day before the procedure to five days postoperatively, patients will be administered Chanyanning granules. The study will observe intraoperative and postoperative bleeding, perforation, and digestive system-related clinical symptoms such as postoperative abdominal pain, bloating, diarrhea, constipation, hematochezia, and fatigue, as well as related inflammatory markers, to determine the therapeutic effect of Chanyanning granules.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The Changyanning group | Active Comparator | The Changyanning group takes Changyanning granules starting from 1 day before surgery until 5 days after surgery. The granules are taken preoperatively at the same time as the first dose of laxative, and postoperatively starting after resuming an open diet. |
|
| The control group | Placebo Comparator | The control group does not use Changyanning granules. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| changyanning granules | Drug | From one day before the procedure to five days postoperatively, patients in the experimental group will be administered Chanyanning granules. |
|
| Measure | Description | Time Frame |
|---|---|---|
| serum interleukin-6 | From enrollment to the end of treatment at 2 weeks | |
| The incidence of complications | The incidence of complications (blood in stool, perforation) and postoperative discomfort symptoms (abdominal pain, abdominal distension, diarrhea, constipation, fatigue, fever, etc.) were compared between the experimental group and the control group (primary endpoints). | From enrollment to the end of treatment at 2 weeks |
| white blood cells | From enrollment to the end of treatment at 2 weeks | |
| C-reactive protein | From enrollment to the end of treatment at 2 weeks | |
| erythrocyte sedimentation rate | From enrollment to the end of treatment at 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| hospital stay | From enrollment to the end of treatment at 2 weeks | |
| hospitalization costs | From enrollment to the end of treatment at 2 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou | Zhejiang | China |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | control |
|